Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

NTBL

Notable Labs Ltd

Jun 25 • 04:00PM ET

0.6188

Dollar change -0.0775
Percentage change -11.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	48.46%	Shs Outstand	9.67M	Perf Week	-20.05%
Market Cap	5.98M	Forward P/E	-	EPS next Y	-1.73	Insider Trans	-3.24%	Shs Float	4.99M	Perf Month	-23.60%
Income	-15.96M	PEG	-	EPS next Q	-0.43	Inst Own	1.46%	Short Float	5.94%	Perf Quarter	-64.44%
Sales	0.48M	P/S	12.47	EPS this Y	56.74%	Inst Trans	-56.53%	Short Ratio	0.73	Perf Half Y	-75.25%
Book/sh	0.27	P/B	2.27	EPS next Y	-16.95%	ROA	-45.61%	Short Interest	0.30M	Perf Year	-93.04%
Cash/sh	2.51	P/C	0.25	EPS next 5Y	-	ROE	-59.52%	52W Range	0.65 - 11.20	Perf YTD	-67.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.40%	ROI	-82.94%	52W High	-94.48%	Beta	0.99
Dividend TTM	-	Quick Ratio	4.63	Sales past 5Y	-	Gross Margin	86.49%	52W Low	-4.80%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.63	EPS Y/Y TTM	56.38%	Oper. Margin	-3398.54%	RSI (14)	33.41	Volatility	9.19% 12.31%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-15.91%	Profit Margin	-3317.05%	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	90.81%	Payout	-	Rel Volume	0.16	Prev Close	0.70
Sales Surprise	-	EPS Surprise	-3.85%	Sales Q/Q	-100.00%	Earnings	May 16	Avg Volume	406.54K	Price	0.62
SMA20	-27.24%	SMA50	-35.46%	SMA200	-76.59%	Trades		Volume	64,273	Change	-11.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-20-22	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-18-22	Resumed	Oppenheimer	Outperform	$5.50
Apr-28-22	Initiated	Chardan Capital Markets	Buy	$5
May-18-21	Initiated	Guggenheim	Buy	$7
Jun-27-19	Initiated	Oppenheimer	Outperform
Mar-09-18	Downgrade	Chardan Capital Markets	Buy → Neutral	$25 → $3
Mar-08-18	Downgrade	Piper Jaffray	Overweight → Neutral
Mar-08-18	Downgrade	H.C. Wainwright	Buy → Neutral	$3
Nov-06-17	Reiterated	Chardan Capital Markets	Buy	$20 → $25
Jun-28-16	Initiated	H.C. Wainwright	Buy	$11
Nov-09-15	Initiated	Piper Jaffray	Overweight
Oct-23-15	Reiterated	Chardan Capital Markets	Buy	$25 → $27.50
Sep-28-15	Reiterated	ROTH Capital	Buy	$13 → $22
Sep-22-15	Initiated	Chardan Capital Markets	Buy	$25
Sep-21-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-22-15	Initiated	ROTH Capital	Buy	$13

Show Previous Ratings

May-24-24 09:55AM	Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now (Zacks)
May-16-24 11:53AM	NTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024 (InvestorPlace)
May-13-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-09-24 04:05PM	Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 (GlobeNewswire) +24.37% -15.54%
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
12:00PM	Loading…
Apr-19-24 12:00PM	Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-12-24 01:53PM	NTBL Stock Earnings: Notable Labs Misses EPS for Q4 2023 (InvestorPlace)
08:00AM	Notable Labs Reports 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-09-24 05:15PM	Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 (GlobeNewswire) -5.37% -13.48%
Apr-08-24 12:00PM	Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform (GlobeNewswire) -9.15%
Mar-05-24 04:35PM	Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform (GlobeNewswire)
Feb-22-24 08:00AM	Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment (GlobeNewswire)
Dec-18-23 08:00AM	Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome (GlobeNewswire) -11.56%
Dec-13-23 12:00PM	Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes (PR Newswire)
Dec-11-23 12:00PM	Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant (PR Newswire) -5.05%
04:30PM	Loading…
Dec-04-23 04:30PM	Notable Labs to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire) -5.36%
Nov-14-23 04:15PM	Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023 (GlobeNewswire) +7.92%
Nov-09-23 04:05PM	Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML (GlobeNewswire)
Oct-16-23 01:01PM	Notable Labs Closes Merger Transaction With VBL Therapeutics (GlobeNewswire) -8.77%
Oct-12-23 09:00AM	VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting (GlobeNewswire) -28.63%
Oct-04-23 08:00AM	VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting (GlobeNewswire)
Sep-06-23 08:00AM	VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC (GlobeNewswire) +8.06%
Aug-14-23 08:28AM	Vascular Biogenics: Q2 Earnings Snapshot (AP Finance)
08:00AM	VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-15-23 06:08PM	Vascular Biogenics: Q1 Earnings Snapshot (AP Finance)
04:01PM	VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-17-23 06:37AM	Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021) (Simply Wall St.)
Mar-14-23 08:00AM	VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-23 08:00AM	VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash (GlobeNewswire)
Feb-23-23 07:00AM	VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement (GlobeNewswire) +29.66%
08:00AM	Loading…
Feb-16-23 08:00AM	VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash (GlobeNewswire)
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
Nov-14-22 07:55PM	Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.49%
04:05PM	VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-22 05:35PM	OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.21%
Sep-02-22 12:36PM	Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07 (Zacks)
12:29PM	Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose (Zacks)
Sep-01-22 04:30PM	VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -5.20%
12:45PM	Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product (Zacks)
Aug-15-22 05:35PM	Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options (GlobeNewswire)
Aug-08-22 10:00AM	Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for (Zacks) +6.55%
Aug-02-22 08:00AM	VBL Therapeutics Announces Workforce Reduction (GlobeNewswire)
Jul-21-22 11:49AM	Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails (Zacks) -11.51%
Jul-20-22 07:35AM	Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low (Benzinga) -79.27%
Jul-19-22 04:01PM	VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer (GlobeNewswire)
May-31-22 08:00AM	VBL Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire) -5.64%
May-17-22 08:15AM	Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.48%
07:00AM	VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-16-22 08:15AM	Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +8.15%
May-12-22 05:45PM	ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +7.14%
May-10-22 08:00AM	VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17 (GlobeNewswire)
May-08-22 10:51AM	What Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares? (Simply Wall St.)
May-04-22 07:55AM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-03-22 08:55AM	Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates (Zacks)
08:00AM	VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May (GlobeNewswire)
Apr-28-22 04:05PM	VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-22 08:00AM	VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer (GlobeNewswire) +8.97%
Apr-01-22 08:36AM	Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar? (Zacks)
Mar-31-22 08:00AM	VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer (GlobeNewswire)
Mar-24-22 03:04PM	Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation (Simply Wall St.)
Mar-23-22 09:25AM	Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +13.99%
07:00AM	VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-14-22 09:57AM	UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23 (GlobeNewswire)
08:00AM	VLB Therapeutics to Report Year-End 2021 Financial Results on March 23 (GlobeNewswire)
Mar-08-22 08:00AM	VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned (GlobeNewswire)
Mar-03-22 08:00AM	VBL Therapeutics to Participate at March Investor Conferences (GlobeNewswire)
Mar-01-22 05:45PM	Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-15-22 04:05PM	VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.77%
Feb-02-22 08:00AM	VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference (GlobeNewswire) -5.26%
Jan-18-22 08:00AM	VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer (GlobeNewswire) -7.06%
Jan-06-22 08:10AM	VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-28-21 09:19AM	BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure (Zacks)
Dec-20-21 07:30AM	VBL Therapeutics Selected for 17.5 Million of Funding from Horizon Europe EIC Accelerator Program (GlobeNewswire) -6.91%
Dec-09-21 11:18AM	Reata (RETA) Falls on Negative Advisory Committee Outcome (Zacks) -5.36%
Dec-07-21 10:26AM	Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug (Zacks) +5.34%
Nov-22-21 10:48AM	Do Insiders Own Lots Of Shares In Vascular Biogenics Ltd. (NASDAQ:VBLT)? (Simply Wall St.)
Nov-18-21 12:00PM	What Makes Vascular Biogenics (VBLT) a New Buy Stock (Zacks)
Nov-15-21 12:25PM	Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-21 03:00PM	Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:00AM	VBL Therapeutics to Report Third Quarter Financial Results on November 15 (GlobeNewswire)
Oct-05-21 08:00AM	VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States (GlobeNewswire)
Sep-17-21 07:00AM	VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer (GlobeNewswire)
Sep-10-21 07:00AM	VBL Therapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-30-21 07:00AM	VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility (GlobeNewswire)
Aug-23-21 01:55PM	We Think Vascular Biogenics (NASDAQ:VBLT) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-16-21 08:25AM	Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.89%
07:00AM	VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-21 10:20AM	10 Biotech Penny Stocks to Buy According to Reddit (Insider Monkey)
Aug-05-21 03:01PM	Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know (Zacks)
07:00AM	VBL Therapeutics to Report Second Quarter Financial Results on August 16 (GlobeNewswire)
Jul-08-21 07:00AM	VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors (GlobeNewswire)
Jun-20-21 02:02PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT (GlobeNewswire)
Jun-17-21 02:51PM	Vascular Biogenics, Ltd. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Jun-16-21 05:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT (PR Newswire)
Jun-15-21 07:00AM	VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer (GlobeNewswire) -11.61%
Jun-03-21 07:00AM	VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer (GlobeNewswire) +10.46%
May-20-21 07:00AM	VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +7.66%
May-11-21 08:35AM	Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)

Notable Labs Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for patients with cancer. Through its proprietary Predictive Medicines Platform the firm predicts whether or not that patient is likely to respond to that specific therapeutic. The company's Predictive Medicines Platform is designed to identify and select patients expected to be clinically responsive prior to their treatment to improve patient outcomes and fast-track clinical development. The firm's product candidate, Volasertib, is a Polo-like Kinase 1 inhibitor. Notable Labs was founded on January 31, 2000 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FR Capital Holdings, L.P.	Former 10% Owner	Jan 02 '24	Sale	1.89	50,000	94,670	880,489	Jan 03 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 29 '23	Sale	1.83	6,000	10,990	930,489	Jan 02 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 28 '23	Sale	2.01	21,500	43,146	936,489	Jan 02 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 27 '23	Sale	2.08	20,033	41,695	957,989	Dec 28 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 26 '23	Sale	2.16	11,456	24,766	978,022	Dec 28 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 22 '23	Sale	2.41	45,000	108,284	989,478	Dec 26 05:00 PM
FR Capital Holdings, L.P.	10% Owner	Dec 21 '23	Sale	2.51	2,867	7,191	1,034,478	Dec 26 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTBL

Notable Labs Ltd

Upgrade your FINVIZ experience